Navitoclax (BCL-xL, BCL-2 and BCL-w antagonist) along with BCL-xL specific antagonist A-1331852, consistently primed NSCLC cells lines but venetoclax (BCL-2 antagonist) did not suggesting that it is the antagonism of BCL-xL that is priming these NSCLC tumor cells (Fig. 1). This evidence concerns the gene BCL2L1 and neoplasm.